Holistic Care for HS Patients: The Power of Multidisciplinary Models

Panelist discusses how Centers of Excellence for hidradenitis suppurativa (HS) differentiate through comprehensive, patient-centered multidisciplinary care models integrating specialized dermatologic, surgical, psychological, and pain management interventions to holistically address complex chronic conditions while navigating systemic health care implementation challenges.

EP: 1.Bridging the Gap in Recognizing Early Symptoms of Hidradenitis Suppurativa

EP: 2.Improving HS Diagnosis and Care Through Better Alignment of Staging and Severity

EP: 3.Addressing Social Determinants of Health in Hidradenitis Suppurativa Care

EP: 4.Economic Implications of Diagnostic Delays in Hidradenitis Suppurativa

EP: 5.Strategies for Equitable Access in Hidradenitis Suppurativa

EP: 6.Partnering With Patient Advocacy Groups to Improve HS Awareness and Outcomes

Now Viewing

EP: 7.Holistic Care for HS Patients: The Power of Multidisciplinary Models

EP: 8.The Case for HS Centers of Excellence: Evidence for Improved Patient Outcomes

EP: 9.Innovating HS Care: Applying Multidisciplinary Lessons to Diagnosis and Management

EP: 10.The Value Proposition: Justifying the Investment in HS Centers of Excellence

EP: 11.Key Takeaways on HS Care: Multidisciplinary Collaboration and Equity Solutions

EP: 12.Navigating HS Management: The Patient Journey

EP: 13.Advancing HS Outcomes: Resource Prioritization and Success Measurement

EP: 14.Tailoring HS Treatment: The Path to Better Patient Outcomes

Video content above is prompted by the following:

• What unique care components distinguish a Center of Excellence from other specialty clinics?
• How does a multidisciplinary care model address the holistic needs of HS patients?
• What are the potential challenges in implementing such a model within existing health systems?

Related Videos

Related Content

Advertisement

June 12th 2025

Zilucoplan Shows Rapid, Durable, Steroid-Sparing Benefits in gMG

Maggie L. Shaw

Zilucoplan (Zilbrysq; UCB) is a once-daily subcutaneous C5 complement inhibitor that has demonstrated long-term treatment benefits in patients who have acetylcholine receptor antibody–positive generalized myasthenia gravis (gMG).

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

June 10th 2025

Fixed-Duration SC Mosunetuzumab Shows 83% PFS at 1 Year in Untreated HTB Follicular Lymphoma

Mary Caffrey

Data presented at ASCO are the latest positive results for a subcutaneous version of this bispecific T-cell engager, which faces competition in follicular lymphoma.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

June 6th 2025

Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?

Mary Caffrey

Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.

June 6th 2025

Oral Ivarmacitinib Shows Promise in Atopic Dermatitis

Maggie L. Shaw

Ivarmacitinib, also known as oral SHR0302, is not yet approved by the FDA, with trials currently exploring its utility in disease settings that include atopic dermatitis and rheumatoid arthritis.

Related Content

Advertisement

June 12th 2025

Zilucoplan Shows Rapid, Durable, Steroid-Sparing Benefits in gMG

Maggie L. Shaw

Zilucoplan (Zilbrysq; UCB) is a once-daily subcutaneous C5 complement inhibitor that has demonstrated long-term treatment benefits in patients who have acetylcholine receptor antibody–positive generalized myasthenia gravis (gMG).

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

June 10th 2025

Fixed-Duration SC Mosunetuzumab Shows 83% PFS at 1 Year in Untreated HTB Follicular Lymphoma

Mary Caffrey

Data presented at ASCO are the latest positive results for a subcutaneous version of this bispecific T-cell engager, which faces competition in follicular lymphoma.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

June 6th 2025

Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?

Mary Caffrey

Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.

June 6th 2025

Oral Ivarmacitinib Shows Promise in Atopic Dermatitis

Maggie L. Shaw

Ivarmacitinib, also known as oral SHR0302, is not yet approved by the FDA, with trials currently exploring its utility in disease settings that include atopic dermatitis and rheumatoid arthritis.